What’s Trending?

The government has announced plans to create a new joint organisation for digital, data and technology, to be called NHSX. [...]
Wed, Feb 20, 2019
Source PharmaTimes
This established, challenging, and free-to-enter competition will close for entry on the 25th February – don't miss out on this great personal development opportunity. [...]
Wed, Feb 20, 2019
Source PharmaTimes
Roche has announced that the FDA has granted Priority Review for entrectinib as a treatment for NTRK fusion-positive, locally advanced or metastatic solid tumours, and to treat metastatic ROS1-positive non-small-cell lung cancer. [...]
Wed, Feb 20, 2019
Source PharmaTimes
MSD's anti-PD-1 therapy Keytruda did not meet its co-primary endpoints in the Phase III KEYNOTE-240 trial involving patients with liver cancer. [...]
Wed, Feb 20, 2019
Source PharmaTimes
Merck & Co.'s immunotherapy Keytruda has been hitting its trial targets so often, it's tempting to think it can't miss. But it can—and Tuesday's data in liver cancer proves it. The question now is what the FDA will do with that failure. [...]
Tue, Feb 19, 2019
Source FiercePharma
A CDMO that has made a habit of snapping up Big Pharma's discarded manufacturing plants has put a former AstraZeneca plant into bankruptcy. [...]
Tue, Feb 19, 2019
Source FiercePharma
Investors have been frustrated with Allergan's reluctance to split up its chairman and CEO roles—particularly activist investor David Tepper. Now, the drugmaker says it supports an investor resolution to split the roles. The catch? It'll hold off until current chief Brent Saunders decides to leave. [...]
Tue, Feb 19, 2019
Source FiercePharma
Activist hedge fund Starboard Value has reportedly hired a proxy solicitor to survey the level of support for the $74 billion Celgene buy. Starboard's interest may be in thwarting the deal by trying to find another buyer for BMS, some analysts have speculated. [...]
Tue, Feb 19, 2019
Source FiercePharma
Pfizer
NEW ORLEANS & Ochsner Health System, Louisiana's largest non-profit academic healthcare system, and Pfizer Inc (NYSE:PFE) have entered into a multi-year strategic alliance to develop innovative models for clinical trials. [...]
Tue, Feb 19, 2019
Source WorldPharmaNews
With their ability to treat a wide a variety of diseases, spherical nucleic acids (SNAs) are poised to revolutionize medicine. But before these digitally designed nanostructures can reach their full potential, researchers need to optimize their various components. A Northwestern University team led by nanotechnology pioneer Chad A. Mirkin has [...]
Tue, Feb 19, 2019
Source WorldPharmaNews
Novartis
Novartis announced that the US Food and Drug Administration (FDA) has approved Egaten® (triclabendazole) for the treatment of fascioliasis in patients six years of age and older. This makes Egaten the only FDA-approved drug for people with this disease and is expected to facilitate broader access to this important drug [...]
Mon, Feb 18, 2019
Source WorldPharmaNews
A pilot program using several clinical decision support tools in the outpatient setting to treat and educate stable ischemic heart disease patients has shown success in improving angina in these patients. Findings from the Florida Cardiovascular Quality Network study were presented at the American College of Cardiology's Cardiovascular Summit in [...]
Mon, Feb 18, 2019
Source WorldPharmaNews
Sponsors submitting pediatric study plans should consider whether a product affects adults and children similarly when choosing an approach, the FDA says. [...]
Fri, Jan 16, 2015
Source FDANews